Weekly Injectable Medical Weight Loss: How Single-Pathway Therapy Works

What single-pathway therapy is

Single-pathway weekly injectables are incretin-based weight-loss medications. After you eat, your gut releases a natural incretin hormone. These medications mimic and prolong that signal: they quiet appetite through receptors in the hypothalamus and brainstem, slow how fast your stomach empties, and improve glucose-dependent insulin release. An oral tablet form of the same pathway also exists for some patients.

How it drives weight loss

The dominant effect for weight management is appetite reduction. Patients describe earlier fullness and a drop in "food noise," the constant background pull toward eating. In its pivotal weight-loss trial (STEP 1), a weekly single-pathway injectable at 2.4 mg produced roughly 15% mean body-weight reduction at 68 weeks in adults without diabetes. Cardiovascular benefit is real too: the SELECT trial showed a 20% reduction in major cardiovascular events, independent of how much weight was lost.

Standard dosing and titration schedule

Single-pathway therapy for weight management is a once-weekly subcutaneous injection. It starts low and steps up roughly every 4 weeks to limit side effects. A common titration schedule is:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

This schedule is a starting framework, not a rule. The right dose is the lowest one that produces steady progress without intolerable side effects. Your provider may hold you at a lower step longer if side effects are significant, or stay below 2.4 mg if a lower dose is working.

Side effects

The common side effects come from the slowed gut: nausea, constipation, diarrhea, and reflux. They are dose-dependent, worst in the first weeks after each increase, and usually settle as your body adapts. Pace of titration matters more than most people realize, going up too fast is where the misery comes from. Uncommon but serious risks include gallbladder issues and pancreatitis (report severe, persistent abdominal pain immediately). These medications carry a boxed warning regarding thyroid C-cell tumors based on rodent data and are not appropriate with a personal or family history of medullary thyroid carcinoma or MEN2.

What KAYU prescribes

KAYU prescribes brand-name, FDA-approved single-pathway injectables dispensed by licensed pharmacies at their published cash-pay price. We do not prescribe compounded versions of these medications. Your provider tells you exactly which product is being prescribed and what it costs before you start.

The KAYU approach

Every incretin-based weight-loss protocol at KAYU starts with labs, not a prescription: fasting insulin, HOMA-IR, HbA1c, full thyroid, ApoB, liver and kidney markers, and a complete blood count. Your provider reads it as a system, because appetite suppression will not fix untreated thyroid dysfunction or a hormone deficiency on its own. The protocol includes a muscle-preservation plan (protein targets and resistance training) and a defined maintenance and off-ramp strategy.